New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVilon vs Cagrilintide

Vilon vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Immune SupportAnti-Aging & Longevity
Vilon
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
Very short as a free dipeptide; effects mediated via gene regulation
~7–10 days
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
1–2 mg SC daily or 5–10 mg oral daily
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
Once daily
Once weekly
Key Benefits
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With